FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

By Sydney Lupkin